Comparison of outcomes for largest CAR-T trials for patients with DLBCL
| . | JULIET42 . | ZUMA-140 . | TRANSCEND43 . |
|---|---|---|---|
| N of enrolled patients | 147 | 111 | 134 |
| N of treated patients | 99 | 101 | 114 |
| Median time from apheresis to infusion | — | 17 d | — |
| ORR, % | 53 | 82 | 75 |
| CR rate | 40 | 54 | 55 |
| Median follow-up, mo | 5.6 | 15.4 | — |
| Duration of response, mo | Not reached | 8.1 | — |
| Rate of any CRS, % | 58 | 93 | 39 |
| Rate of grade ≥3 CRS, %* | 15 | 13 | 1 |
| Rate of any neurotoxicity, % | 21 | 64 | 23 |
| Rate of grade ≥3 neurotoxicity, % | 12 | 28 | 13 |
| Frequency of tocilizumab use, % | 15 | 43 | 10 |
| Frequency of steroid use, % | 11 | 27 | 9 |
| . | JULIET42 . | ZUMA-140 . | TRANSCEND43 . |
|---|---|---|---|
| N of enrolled patients | 147 | 111 | 134 |
| N of treated patients | 99 | 101 | 114 |
| Median time from apheresis to infusion | — | 17 d | — |
| ORR, % | 53 | 82 | 75 |
| CR rate | 40 | 54 | 55 |
| Median follow-up, mo | 5.6 | 15.4 | — |
| Duration of response, mo | Not reached | 8.1 | — |
| Rate of any CRS, % | 58 | 93 | 39 |
| Rate of grade ≥3 CRS, %* | 15 | 13 | 1 |
| Rate of any neurotoxicity, % | 21 | 64 | 23 |
| Rate of grade ≥3 neurotoxicity, % | 12 | 28 | 13 |
| Frequency of tocilizumab use, % | 15 | 43 | 10 |
| Frequency of steroid use, % | 11 | 27 | 9 |
CRS, cytokine release syndrome.
Grading varied among studies.